A study hosted and indexed on the HEAL Platform. Note that if the study has more than one aim, a single form should be completed and the multi-select answer options should be used to provide information about each of the aims.
The title or name of the study. For NIH-funded studies, this will generally be equivalent to the NIH application ID title
A description of or abstract for the study. For NIH-funded studies , this will generally be equivalent to the NIH application ID abstract text
Study nickname, alternative title, abbreviation, or acronym (e.g. many people shorten the name of the HEAL Adolescent Brain Cognitive Development study to ABCD)
An alternative description of or abstract for the study. - Generally, for studies with an NIH appl id, if this field is filled out, the text will be searchable on the Platform, but the NIH appl id abstract text will be the study description displayed for the study in the Platform study table entry.
NIH application ID; only applicable if study is funded by NIH
URL link to the NIH application ID NIH RePORTER webpage; only applicable if study is funded by NIH
Must match regular expression:^https?:// ClinicalTrials.gov study ID; only applicable if study is a reportable clinical trial and registered on ClinicalTrials.gov
Describe the data repositories to which data or other shareable products produced by the study will be submitted by the study authors and stored for long-term access; one item in this array per repository
Name of a repository in which data or other shareable research products are submitted for storage by study author
Unique identifier assigned to the study at that repository; usually a number or combination of standard letters and numbers (e.g. study identifiers on ClinicalTrials.gov are generally in the format: NCT12345678)
Unique persistent identifier assigned to the study at that repository; usually a doi
The official citation the repository requests be used to cite the study/data when the study/data is discovered/accessed via the repository; will likely follow the format: Principal Investigator(s). Title. Place-of-Distribution and Distributor, Date-of-Distribution. DOI. version (where distributor will be the repository name)
ID of the CEDAR HEAL Study-level Core Metadata Template instance created for this study
any other websites officially associated with this study that provide additional information about the study
Whether or not the study is funded by the NIH HEAL initiative
Whether or not the study is related to a study group or collection(s) by some administrative mechanism, or belongs to a group or collection of studies (e.g. SAMHSA performs a survey called the National Survey of Substance Abuse Treatment Services (N-SSATS) every year; each annual survey may be registered as a separate study that belongs to a collection called the N-SSATS collection)
If this study belongs to a study group or collection(s), this is the name or identifier of the study group or collection(s) (e.g. SAMHSA performs a survey called the National Survey of Substance Abuse Treatment Services (N-SSATS) every year; each annual survey may be registered as a separate study that belongs to a collection called the N-SSATS collection)
Describe the grants and other funding supporting the study; one item in this array per grant/award or funding source
Name of a the granting agency or organization funding the study; include sub-agency administrative entity as second element in array if applicable (e.g. National Institute of Health, National Institute on Drug Abuse)
Abbreviation for the name of the granting agency or organization funding the study; include abbreviation for sub-agency administrative entity as second element in array if applicable (e.g. NIH, NIDA)
Type of granting agency or organization funding the study
The geographic reach of the granting agency or organization funding the study
The grant award ID or number. For NIH-funded studies this will be the project or award number and is distinct from the NIH application ID
The grant award name. For NIH-funded studies this will be the project or award name and is distinct from the name or title associated with the NIH application ID
Describe the primary and co-investigators of the study; one item in this array per investigator
First name of study primary or co-investigator
Middle initial of study primary or co-investigator
Last name of study primary or co-investigator
Institutional affiliation of study primary or co-investigator
Add a structured identifier(s) for the investigator; one item in this array per structured identifier; e.g. one item for providing ORCID, another for providing RAS passport
Type of identifier that will be provided
Value of the identifier of the type specified by ID_type
Persistent identifier assigned to the study on the HEAL Platform; probably a HEAL Platform-branded doi
The official citation the HEAL Platform will request be used to cite the study/data when the study/data is discovered/accessed via the Platform; will likely follow the format: Principal Investigator(s). Title. Place-of-Distribution and Distributor, Date-of-Distribution. DOI. version (where distributor will be: Platform via [Repository Name])
Describe the contact person(s) for the study. This is the person(s) who should be contacted for questions about the study; will be auto-set as NIH contact PI(s) if NIH-funded; one item in this array per contact person
First name of study contact
Middle initial of study contact
Last name of study contact
Institutional affiliation of study contact
Institutional email of study contact
Describe the person(s) who will register the study on the HEAL Platform. This person(s) must be authorized to access the study registration page/process on the HEAL Platform; will be auto-set as NIH contact PI(s) if NIH-funded; one item in this array per registrant
First name of study registrant
Middle initial of study registrant
Last name of study registrant
Institutional affiliation of study registrant
Institutional email of study registrant
Indicate whether or not the study will collect/produce (primary or secondary) data
If study will collect/produce data, indicate whether all, some, or none of the data will be made available
If study will collect/produce data, and make at least some of that data available, indicate whether all, some, or none of the data will have restriction(s) on access beyond acknowledgement and signing of a minimal DSA
If study will collect/produce data, indicate whether the study has not started, has started, or has finished data collection/production activities
If the study will collect/produce data and make at least some of the data available, indicate whether the study has not started, has started, or has finished data release activities
If the study will collect/produce data, indicate the anticipated date when data collection/production will begin
If the study will collect/produce data, indicate the anticipated date when data collection/production will end (data collection/production is complete)
If study will collect/produce data and make at least some of the data available, indicate the anticipated date when first data will be released
If study will produce data and make at least some of the data available, indicate the anticipated date when last data will be released (data release is complete)
Indicate whether or not the study will produce shareable products other than data
List of the doi for any/all primary study publications that use the study data; include any papers, books, articles, blog posts, etc. authored by the investigators or team responsible for the study; one item in this array per publication/doi
Simple, one-sentence take-away conclusion(s) from study author publications; one item in this array per single-sentence conclusion (e.g. item #1: Provision of MAT rx to men with documented OUD leaving jail reduces overdose risk by 9%; item #2: Provision of MAT rx plus case management support to men with documented OUD leaving jail reduces overdose risk by 30%; item 3: Provision of MAT rx plus case management support to men with documented OUD leaving jail is more effective than provision of MAT rx alone at reducing risk of OUD overdose)
List of the doi for any/all secondary study publications that use the study data; include any papers, books, articles, blog posts, etc. authored by persons OTHER THAN the investigators or team responsible for the study; one item in this array per publication/doi
Whether the study is primarily focused on learning more about a human opioid or pain CONDITION or on discovering, or learning more about a TREATMENT OF A CONDITION, intervention, or solution for a human opioid or pain condition. This may be quite simple to infer for human subject studies. For studies not involving human subjects, please consider how/where the study will most substantially contribute to the HEAL Initiative translational purpose of learning more about human opioid and pain conditions and driving development of solutions to these conditions. Note there are some studies that are not related to a specific condition or the treatment of a condition. An example of a study like this is the National Institute on Drug Abuse (NIDA) study Incarceration Effects on Medicaid Status. If a study like this does not apply to a condition or treatment, this question can be left blank.Choose one.
What types of determinants and/or mechanisms related to human opioid use or pain conditions is the study investigating and/or measuring (e.g. A study investigating differential pain/nociception signaling in persons living in neighborhoods with high versus low social cohesion might choose both 'Biology and Health' and 'Social Determinants'). Choose as many as apply.
The high-level category or type/stage of research being conducted
Is the study collecting data itself to analyze and draw conclusions or is it leveraging data collected by other entities to analyze and draw conclusions
Whether the study is observational (no explicit intervention) or experimental (some explicit intervention)
What is the actual species or entity that is experimentally or observationally studied in the research; each HEAL study will have translational relevance to humans, but not all HEAL studies directly study humans
The overarching study type and more granular study design. Choose as many as apply
If the study is investigating a treatment, intervention, or solution to a human opioid or pain condition, what type of investigation is the study undertaking? at what stage in the treatment investigation process does this study lie?
Is the treatment, intervention, or solution that my study is relevant to meant to prevent the occurrance of a condition (e.g. development of a non-opioid drug for pain to prevent opioid exposure and addiction, case management and MAT for pregnant women to prevent in utero exposure to opioids, safe needle exchange center to prevent spread of blood borne diseases among people using heroin), treat an occurrance of a condition (e.g. naloxone to treat opioid overdose, physical therapy to treat existing pain from a back injury) , and/or is it a harm reduction mechanism (e.g. safe needle exchange reduces harm associated with heroin addiction/use, decriminalization of heroin possession or use reduces the harm associated with heroin addiction/use)
Is the treatment, intervention, or solution that my study is relevant to totally novel, is it totally established, does it have some element of novelty added to an established intervention (novel added to established, established used in a novel population, setting, or combination)?
Is the treatment, intervention, or solution that my study is relevant to applied at the individual level (e.g. a doctor prescribes a drug or physical therapy regimen to a patient) or at the population/community/group level (e.g. a city changes good samaritan naloxone laws, or implements a safe needle exchange center, or adds park maintenance resources to the budget to provide more access to outside places to exercise)?
Classify the treatment, intervention, or solution the study is relevant to by broad type of intervention. Choose as many as apply
Considering the study in a translational context, to humans with which broad category(ies) of opioid use or pain conditions are the study results intended to apply. Choose as many as apply
Each HEAL study will be doing work that is relevant to a human opioid and/or pain condition. What does this study intend to learn about the condition? If the study is investigating a treatment, intervention, or solution, please choose 'Treatment of Condition'. Choose as many as apply
If the study will be doing work that is relevant to a human PAIN condition category, is the study focusing on pain caused by a specific condition? e.g. Cancer, fibromyalgia, arthritis, occupational injury, sports injury, car accident, surgical procedure. If yes, please indicate the causal condition(s) here - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
If the study will be doing work that is relevant to a human PAIN condition category, and the pain condition has a causal condition (specified above), is the study focusing its investigation on the causal condition, or on the pain resulting from the causal condition? e.g. In a study of effective treatments for fibromyalgia/fibromyalgia pain, is the study focused on fibromyalgia disease-modifying treatments, or on treatments that address the symptomology of pain? Choose as many as apply
Considering the study in a translational context, to humans with which detailed type of opioid use or pain conditions are the study results intended to apply? Each HEAL study will be doing work that is relevant to a human opioid and/or pain condition; You indicated the broad category of condition(s) the study is focusing on or relevant to above. Here, please indicate the study focus condition(s) in detail. Choose as many as apply - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
If the outcome condition(s) the study hopes to impact or measure is different than the treatment or study target condition (e.g. testing a disease-modifying fibromyaligia treatment but measuring depression, physical and social function, and neurologic pain such as headaches as the main outcomes). Please indicate the study outcome condition(s) here. Choose as many as apply - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
If the study is measuring or tracking other human health conditions besides the treatment or study target condition and outcome condition, please indicate the other tracked/measured condition(s) here. Choose as many as apply - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
Considering the study in a translational context, to humans of which gender identity(ies) are the study results intended to apply and/or likely to generalize to.
Considering the study in a translational context, to humans of which sexual identity(ies) are the study results intended to apply and/or likely to generalize to.
Considering the study in a translational context, to humans of which biological sexes are the study results intended to apply and/or likely to generalize to.
Considering the study in a translational context, to humans of which age or developmental stage are the study results intended to apply and/or likely to generalize to
Considering the study in a translational context, which special IRB human vulnerability conditions are the study results intended to address or apply to?
For studies with human subjects, from which geographic location(s) are subjects recruited. If subjects are recruited in the US nationally, choose only US - national. If subject are recruited in the US only in specific state(s), choose US - Specific States, then please also select the abbreviation of each of the specific states from which subjects are recruited. If subjects are recruited in the US from specific county(ies) within specific state(s), please choose US - Specific States and US - Specific Counties, and choose the abbreviation of each specific state from which subjects are recruited
Does the study produce/collect quantitative data?, qualitative data? Choose as many as apply
What is the source of the data the study will produce/collect. Choose as many as apply
What is the type of the data the study will produce/collect. Choose as many as apply
For studies with human subjects, is the data collected at the individual or population level?
For studies with human subjects, what is the expected number of subjects for which data will be collected? If unit of data collection is individuals this is the expected number of individuals, and if the unit of data collection is populations/clusters this is the expected number of populations/clusters
For studies with human subjects, is the data analyzed at the individual or population level?
For studies with human subjects, what is the expected number of subjects at the level at which data will be analyzed? If unit of data analysis is individuals this is the expected number of individuals, and if the unit of data analysis is populations/clusters this is the expected number of populations/clusters
For studies with human subjects that will make at least some data available, will data be made available at the individual subject level or some level of aggregation?
For studies with human subjects, will geographic data be collected? if so, what level of geographic detail will be collected?
For studies with human subjects that collect geographic data and will make at least some data available, will geographic data be made available? if so, what level of geographic detail will be made available?
A study hosted and indexed on the HEAL Platform. Note that if the study has more than one aim, a single form should be completed and the multi-select answer options should be used to provide information about each of the aims.
The title or name of the study. For NIH-funded studies, this will generally be equivalent to the NIH application ID title
A description of or abstract for the study. For NIH-funded studies , this will generally be equivalent to the NIH application ID abstract text
Study nickname, alternative title, abbreviation, or acronym (e.g. many people shorten the name of the HEAL Adolescent Brain Cognitive Development study to ABCD)
An alternative description of or abstract for the study. - Generally, for studies with an NIH appl id, if this field is filled out, the text will be searchable on the Platform, but the NIH appl id abstract text will be the study description displayed for the study in the Platform study table entry.
NIH application ID; only applicable if study is funded by NIH
URL link to the NIH application ID NIH RePORTER webpage; only applicable if study is funded by NIH
Must match regular expression:^https?:// ClinicalTrials.gov study ID; only applicable if study is a reportable clinical trial and registered on ClinicalTrials.gov
Describe the data repositories to which data or other shareable products produced by the study will be submitted by the study authors and stored for long-term access; one item in this array per repository
No Additional ItemsName of a repository in which data or other shareable research products are submitted for storage by study author
Unique identifier assigned to the study at that repository; usually a number or combination of standard letters and numbers (e.g. study identifiers on ClinicalTrials.gov are generally in the format: NCT12345678)
Unique persistent identifier assigned to the study at that repository; usually a doi
The official citation the repository requests be used to cite the study/data when the study/data is discovered/accessed via the repository; will likely follow the format: Principal Investigator(s). Title. Place-of-Distribution and Distributor, Date-of-Distribution. DOI. version (where distributor will be the repository name)
ID of the CEDAR HEAL Study-level Core Metadata Template instance created for this study
Other websites officially associated with this study that provide additional information about the study
No Additional ItemsWhether or not the study is funded by the NIH HEAL initiative
Whether or not the study is related to a study group or collection(s) by some administrative mechanism, or belongs to a group or collection of studies (e.g. SAMHSA performs a survey called the National Survey of Substance Abuse Treatment Services (N-SSATS) every year; each annual survey may be registered as a separate study that belongs to a collection called the N-SSATS collection)
If this study belongs to a study group or collection(s), this is the name or identifier of the study group or collection(s) (e.g. SAMHSA performs a survey called the National Survey of Substance Abuse Treatment Services (N-SSATS) every year; each annual survey may be registered as a separate study that belongs to a collection called the N-SSATS collection)
No Additional ItemsDescribe the grants and other funding supporting the study; one item in this array per grant/award or funding source
No Additional ItemsName of a the granting agency or organization funding the study; include sub-agency administrative entity as second element in array if applicable (e.g. National Institute of Health, National Institute on Drug Abuse)
No Additional ItemsAbbreviation for the name of the granting agency or organization funding the study; include abbreviation for sub-agency administrative entity as second element in array if applicable (e.g. NIH, NIDA)
No Additional ItemsType of granting agency or organization funding the study
The geographic reach of the granting agency or organization funding the study
The grant award ID or number. For NIH-funded studies this will be the project or award number and is distinct from the NIH application ID
The grant award name. For NIH-funded studies this will be the project or award name and is distinct from the name or title associated with the NIH application ID
Describe the primary and co-investigators of the study; one item in this array per investigator
No Additional ItemsFirst name of study primary or co-investigator
Middle initial of study primary or co-investigator
Last name of study primary or co-investigator
Institutional affiliation of study primary or co-investigator
Add a structured identifier(s) for the investigator; one item in this array per structured identifier; e.g. one item for providing ORCID, another for providing RAS passport
No Additional ItemsType of identifier that will be provided
Value of the identifier of the type specified by ID_type
Persistent identifier assigned to the study on the HEAL Platform; probably a HEAL Platform-branded doi
The official citation the HEAL Platform will request be used to cite the study/data when the study/data is discovered/accessed via the Platform; will likely follow the format: Principal Investigator(s). Title. Place-of-Distribution and Distributor, Date-of-Distribution. DOI. version (where distributor will be: Platform via [Repository Name])
Describe the contact person(s) for the study. This is the person(s) who should be contacted for questions about the study; will be auto-set as NIH contact PI(s) if NIH-funded; one item in this array per contact person
No Additional ItemsFirst name of study contact
Middle initial of study contact
Last name of study contact
Institutional affiliation of study contact
Institutional email of study contact
Describe the person(s) who will register the study on the HEAL Platform. This person(s) must be authorized to access the study registration page/process on the HEAL Platform; will be auto-set as NIH contact PI(s) if NIH-funded; one item in this array per registrant
No Additional ItemsFirst name of study registrant
Middle initial of study registrant
Last name of study registrant
Institutional affiliation of study registrant
Institutional email of study registrant
Indicate whether or not the study will collect/produce (primary or secondary) data
If study will collect/produce data, indicate whether all, some, or none of the data will be made available
If study will collect/produce data, and make at least some of that data available, indicate whether all, some, or none of the data will have restriction(s) on access beyond acknowledgement and signing of a minimal DSA
If study will collect/produce data, indicate whether the study has not started, has started, or has finished data collection/production activities
If the study will collect/produce data and make at least some of the data available, indicate whether the study has not started, has started, or has finished data release activities
If the study will collect/produce data, indicate the anticipated date when data collection/production will begin
If the study will collect/produce data, indicate the anticipated date when data collection/production will end (data collection/production is complete)
If study will collect/produce data and make at least some of the data available, indicate the anticipated date when first data will be released
If study will produce data and make at least some of the data available, indicate the anticipated date when last data will be released (data release is complete)
Indicate whether or not the study will produce shareable products other than data
List of the doi for any/all primary study publications that use the study data; include any papers, books, articles, blog posts, etc. authored by the investigators or team responsible for the study; one item in this array per publication/doi
No Additional ItemsSimple, one-sentence take-away conclusion(s) from study author publications; one item in this array per single-sentence conclusion (e.g. item #1: Provision of MAT rx to men with documented OUD leaving jail reduces overdose risk by 9%; item #2: Provision of MAT rx plus case management support to men with documented OUD leaving jail reduces overdose risk by 30%; item 3: Provision of MAT rx plus case management support to men with documented OUD leaving jail is more effective than provision of MAT rx alone at reducing risk of OUD overdose)
No Additional ItemsList of the doi for any/all secondary study publications that use the study data; include any papers, books, articles, blog posts, etc. authored by persons OTHER THAN the investigators or team responsible for the study; one item in this array per publication/doi
No Additional ItemsWhether the study is primarily focused on learning more about a human opioid or pain CONDITION or on discovering, or learning more about a TREATMENT OF A CONDITION, intervention, or solution for a human opioid or pain condition. This may be quite simple to infer for human subject studies. For studies not involving human subjects, please consider how/where the study will most substantially contribute to the HEAL Initiative translational purpose of learning more about human opioid and pain conditions and driving development of solutions to these conditions. Note there are some studies that are not related to a specific condition or the treatment of a condition. An example of a study like this is the National Institute on Drug Abuse (NIDA) study Incarceration Effects on Medicaid Status. If a study like this does not apply to a condition or treatment, this question can be left blank.Choose one.
What types of determinants and/or mechanisms related to human opioid use or pain conditions is the study investigating and/or measuring (e.g. A study investigating differential pain/nociception signaling in persons living in neighborhoods with high versus low social cohesion might choose both 'Biology and Health' and 'Social Determinants'). Choose as many as apply.
No Additional ItemsThe high-level category or type/stage of research being conducted
No Additional ItemsIs the study collecting data itself to analyze and draw conclusions or is it leveraging data collected by other entities to analyze and draw conclusions
Whether the study is observational (no explicit intervention) or experimental (some explicit intervention)
What is the actual species or entity that is experimentally or observationally studied in the research; each HEAL study will have translational relevance to humans, but not all HEAL studies directly study humans
No Additional ItemsThe overarching study type and more granular study design. Choose as many as apply
No Additional ItemsConsidering the study in a translational context, to humans of which gender identity(ies) are the study results intended to apply and/or likely to generalize to.
No Additional ItemsConsidering the study in a translational context, to humans of which sexual identity(ies) are the study results intended to apply and/or likely to generalize to.
No Additional ItemsConsidering the study in a translational context, to humans of which biological sexes are the study results intended to apply and/or likely to generalize to.
No Additional ItemsConsidering the study in a translational context, to humans of which age or developmental stage are the study results intended to apply and/or likely to generalize to
No Additional ItemsConsidering the study in a translational context, which special IRB human vulnerability conditions are the study results intended to address or apply to?
No Additional ItemsFor studies with human subjects, from which geographic location(s) are subjects recruited. If subjects are recruited in the US nationally, choose only US - national. If subject are recruited in the US only in specific state(s), choose US - Specific States, then please also select the abbreviation of each of the specific states from which subjects are recruited. If subjects are recruited in the US from specific county(ies) within specific state(s), please choose US - Specific States and US - Specific Counties, and choose the abbreviation of each specific state from which subjects are recruited
If the study is investigating a treatment, intervention, or solution to a human opioid or pain condition, what type of investigation is the study undertaking? at what stage in the treatment investigation process does this study lie?
No Additional ItemsIs the treatment, intervention, or solution that my study is relevant to meant to prevent the occurrance of a condition (e.g. development of a non-opioid drug for pain to prevent opioid exposure and addiction, case management and MAT for pregnant women to prevent in utero exposure to opioids, safe needle exchange center to prevent spread of blood borne diseases among people using heroin), treat an occurrance of a condition (e.g. naloxone to treat opioid overdose, physical therapy to treat existing pain from a back injury) , and/or is it a harm reduction mechanism (e.g. safe needle exchange reduces harm associated with heroin addiction/use, decriminalization of heroin possession or use reduces the harm associated with heroin addiction/use)
Is the treatment, intervention, or solution that my study is relevant to totally novel, is it totally established, does it have some element of novelty added to an established intervention (novel added to established, established used in a novel population, setting, or combination)?
No Additional ItemsIs the treatment, intervention, or solution that my study is relevant to applied at the individual level (e.g. a doctor prescribes a drug or physical therapy regimen to a patient) or at the population/community/group level (e.g. a city changes good samaritan naloxone laws, or implements a safe needle exchange center, or adds park maintenance resources to the budget to provide more access to outside places to exercise)?
No Additional ItemsClassify the treatment, intervention, or solution the study is relevant to by broad type of intervention. Choose as many as apply
No Additional ItemsConsidering the study in a translational context, to humans with which broad category(ies) of opioid use or pain conditions are the study results intended to apply. Choose as many as apply
No Additional ItemsEach HEAL study will be doing work that is relevant to a human opioid and/or pain condition. What does this study intend to learn about the condition? If the study is investigating a treatment, intervention, or solution, please choose 'Treatment of Condition'. Choose as many as apply
No Additional ItemsIf the study will be doing work that is relevant to a human PAIN condition category, is the study focusing on pain caused by a specific condition? e.g. Cancer, fibromyalgia, arthritis, occupational injury, sports injury, car accident, surgical procedure. If yes, please indicate the causal condition(s) here - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
No Additional ItemsIf the study will be doing work that is relevant to a human PAIN condition category, and the pain condition has a causal condition (specified above), is the study focusing its investigation on the causal condition, or on the pain resulting from the causal condition? e.g. In a study of effective treatments for fibromyalgia/fibromyalgia pain, is the study focused on fibromyalgia disease-modifying treatments, or on treatments that address the symptomology of pain? Choose as many as apply
No Additional ItemsConsidering the study in a translational context, to humans with which detailed type of opioid use or pain conditions are the study results intended to apply? Each HEAL study will be doing work that is relevant to a human opioid and/or pain condition; You indicated the broad category of condition(s) the study is focusing on or relevant to above. Here, please indicate the study focus condition(s) in detail. Choose as many as apply - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
No Additional ItemsIf the outcome condition(s) the study hopes to impact or measure is different than the treatment or study target condition (e.g. testing a disease-modifying fibromyaligia treatment but measuring depression, physical and social function, and neurologic pain such as headaches as the main outcomes). Please indicate the study outcome condition(s) here. Choose as many as apply - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
No Additional ItemsIf the study is measuring or tracking other human health conditions besides the treatment or study target condition and outcome condition, please indicate the other tracked/measured condition(s) here. Choose as many as apply - Values will be restricted to NLM MeSH Diseases - see Branch 'C' here: https://meshb-prev.nlm.nih.gov/treeView
No Additional ItemsDoes the study produce/collect quantitative data?, qualitative data? Choose as many as apply
No Additional ItemsWhat is the source of the data the study will produce/collect. Choose as many as apply
No Additional ItemsWhat is the type of the data the study will produce/collect. Choose as many as apply
No Additional ItemsFor studies with human subjects, is the data collected at the individual or population level?
No Additional ItemsFor studies with human subjects, what is the expected number of subjects for which data will be collected? If unit of data collection is individuals this is the expected number of individuals, and if the unit of data collection is populations/clusters this is the expected number of populations/clusters
For studies with human subjects, is the data analyzed at the individual or population level?
No Additional ItemsFor studies with human subjects, what is the expected number of subjects at the level at which data will be analyzed? If unit of data analysis is individuals this is the expected number of individuals, and if the unit of data analysis is populations/clusters this is the expected number of populations/clusters
For studies with human subjects that will make at least some data available, will data be made available at the individual subject level or some level of aggregation?
No Additional ItemsFor studies with human subjects, will geographic data be collected? if so, what level of geographic detail will be collected?
No Additional ItemsFor studies with human subjects that collect geographic data and will make at least some data available, will geographic data be made available? if so, what level of geographic detail will be made available?
No Additional Items